醒脑静注射液辅助治疗脑梗死的有效性及安全性研究

目的研究醒脑静注射液辅助治疗脑梗死的有效性及安全性。方法100例脑梗死患者,根据治疗方法不同分为对照组和观察组,各50例。对照组每晚口服阿司匹林肠溶片+阿托伐他汀钙片。观察组在对照组的给药基础上静脉滴注醒脑静注射液。比较两组患者临床疗效、治疗前后超敏C反应蛋白(hs-CRP)和白细胞介素-6(IL-6)水平、治疗前后美国国立卫生研究院卒中量表(NIHSS)评分及Barthel指数变化情况、不良反应发生情况。结果治疗后,两组hs-CRP、IL-6水平均低于本组治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组NIHSS评分、Barthel指数均优于本组治疗前,且观察组NIHSS评分、Barthel指数分别为(5.58±2.70)、(78.88±15.93)分,优于对照组的(7.70±2.13)、(61.89±12.72)分,差异有统计学意义(P<0.05)。观察组治疗总有效率为94.00%高于对照组80.00%,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P<0.05)。结论与常规给药治疗相比,选用醒脑静注射液辅助治疗脑梗死更加有效,能降低hs-CRP和IL-6等炎症因子表达水平,改善神经损伤、日常活动能力,安全性高,值得临床推广应用。

Study on the effectiveness and safety of Xingnaojing injection in adjuvant treatment of cerebral infarction

Objective To study the effectiveness and safety of Xingnaojing injection in adjuvant treatment of cerebral infarction.Methods A total of 100 patients with cerebral infarction were divided into control group and observation group according to different treatment methods,with 50 cases in each group.The control group was treated with aspirin enteric-coated tablets+atorvastatin calcium tablets every night,and the observation group received Xingnaojing injection intravenously on the basis of the control group.The clinical efficacy,high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)levels,National Institutes of Health stroke scale(NIHSS)score and Barthel index before and after treatment,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the hs-CRP and IL-6 of the two groups were lower than those before treatment,and the observation group was lower than the control group.All the difference was statistically significant(P<0.05).After treatment,the NIHSS score and Barthel index of the two groups were better than those before treatment,and NIHSS score(5.58±2.70)points and Barthel index(78.88±15.93)points of the observation group were better than(7.70±2.13)and(61.89±12.72)points of the control group.All the difference was statistically significant(P<0.05).The total effective rate 94.00%of the observation group was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P<0.05).Conclusion Compared with conventional treatment,Xingnaojing injection is more effective in the adjuvant treatment of cerebral infarction,which can reduce the expression levels of inflammatory factors such as hs-CRP and IL-6,improve nerve injury and daily activities with high safety.It is worthy of clinical promotion and application.